The discontinuation rate due to side effects is lower for Zepbound (9.1%) than for Retatrutide (11.2%), despite Retatrutides superior efficacy
Wadden, T.A., Bailey, T.S., Billings, L.K., Davies, M., Frias, J.P., Koroleva, A., Lingvay, I., ONeil, P.M., Rubino, D.M., Skovgaard, D., Wallenstein, S.O.R., Garvey, W.T
A total of 1156 (2.1%) patients had switched to another SGLT2 inhibitor
One of our patients, Moira, shared her story on Episode 81 of our podcast
This extended period allows even the most sensitive individuals to fully adjust to the initial receptor activation